Moreover, MGO administration increased the levels of cytokines (IL-1β, IL-6, and TNF-α) in the serum, which led to neuropsychiatric disorders and depression as shown in behavior tests (i.e., OFT, TST, and FST) (Figure 4F-H and Figure 5B-D). This evidence concerns the gene IL1B and depressive symptom measurement.